Record overview
Status and phase
Status: SUSPENDED
Phase: PHASE2
Sponsor: National Cancer Institute (NCI)
Condition: Progressive Glioblastoma, Recurrent Glioblastoma
NCT06325683
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
Scheduled Interim Monitoring